Pub Date : 2024-08-10DOI: 10.1177/0976500x241266049
Sonia Mandal, P. Sawarkar, Varinder Singh, Shweta Parwe, G. Sawarkar
Parkinson’s disease (PD) affects the central nervous system and is primarily characterized by the degeneration of dopamine-producing cells in the substantia nigra. Early signs include tremor, rigidity, bradykinesia, and postural instability, with later cognitive, sensory, sleep, and emotional issues. Ayurveda correlates these symptoms with Kampavata, primarily linked to Vata (bio-entities) imbalance. The prime aim of this paper is to study Panchakarma’s efficacy in managing Kampavata (PD). This is a case presentation of a 55-year-old male patient who has experienced tremors in the left upper and lower limbs, numbness in the left lower limb, loss of balance for 10 years, abnormal facial expression (masked face), difficulty in speech, and sleep disturbance for 5 years. The patient was treated with Panchakarma therapy for 30 days. Following treatment, the patient exhibited significant improvement in symptoms, assessed using the PD composite scale, with the total score decreasing from 68 to 19, along with evaluated by specific examination, bradykinesia test, reflexes, functional activities, and clinical features also notably improved. Panchakarma therapy, rooted in Ayurvedic principles, shows promise in managing Kampavata, associated with PD. Conservative management focuses on Vata balance, which offers substantial comfort and enhances patient quality of life. Panchakarma therapy presents a potential avenue for treating Kampavata, addressing symptoms associated with PD, and improving patient satisfaction and well-being. Further research is warranted to validate these findings and explore the broader applicability of Ayurvedic approaches in neurodegenerative conditions.
{"title":"Management of Kampavata (Parkinson’s Disease) Through Panchakarma: A Successful Case Study","authors":"Sonia Mandal, P. Sawarkar, Varinder Singh, Shweta Parwe, G. Sawarkar","doi":"10.1177/0976500x241266049","DOIUrl":"https://doi.org/10.1177/0976500x241266049","url":null,"abstract":"Parkinson’s disease (PD) affects the central nervous system and is primarily characterized by the degeneration of dopamine-producing cells in the substantia nigra. Early signs include tremor, rigidity, bradykinesia, and postural instability, with later cognitive, sensory, sleep, and emotional issues. Ayurveda correlates these symptoms with Kampavata, primarily linked to Vata (bio-entities) imbalance. The prime aim of this paper is to study Panchakarma’s efficacy in managing Kampavata (PD). This is a case presentation of a 55-year-old male patient who has experienced tremors in the left upper and lower limbs, numbness in the left lower limb, loss of balance for 10 years, abnormal facial expression (masked face), difficulty in speech, and sleep disturbance for 5 years. The patient was treated with Panchakarma therapy for 30 days. Following treatment, the patient exhibited significant improvement in symptoms, assessed using the PD composite scale, with the total score decreasing from 68 to 19, along with evaluated by specific examination, bradykinesia test, reflexes, functional activities, and clinical features also notably improved. Panchakarma therapy, rooted in Ayurvedic principles, shows promise in managing Kampavata, associated with PD. Conservative management focuses on Vata balance, which offers substantial comfort and enhances patient quality of life. Panchakarma therapy presents a potential avenue for treating Kampavata, addressing symptoms associated with PD, and improving patient satisfaction and well-being. Further research is warranted to validate these findings and explore the broader applicability of Ayurvedic approaches in neurodegenerative conditions.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141920243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-08DOI: 10.1177/0976500x241253645
Torisa Roy, T. Mazumder, Priyanka Sharma, Tamali Roy, T. Nag, Samik Bindu, S. Dasgupta, H. Yasmin
Delayed-type hypersensitivity (DTH) reactions represent a clinically important class of immune responses that have wide-ranging implications in various health and disease conditions. The existing anti-inflammatory drugs to treat DTH have several shortcomings including severe side-effects. Thus, a new plant-derived anti-inflammatory drug with no or less toxicity would be effective in treating DTH. The Cleome genus has been routinely used to cure various ailments including inflammation. This study investigates the anti-inflammatory properties of the ethanolic leaf extract of Cleome spinosa (CSE) in a DTH model for the first time. DTH response was induced by 2, 4-di nitro-fluorobenzene in the mouse foot pad. Histological sectioning of the paw was carried out to find changes in the architecture of the tissue. Serum tumour necrosis factor-alpha (TNF-α) was estimated through enzyme linked immunosorbent assay (ELISA), and the bioactive compounds present in CSE were analysed through reversed phase-high-performance liquid chromatography . With CSE treatment, the oedema in the resensitized paw alleviated faster with no loss of digits compared to the controls. Histological study of the resensitized paw showed less dermal and sub-dermal thickening and less collagen deposition that regained normal tissue architecture during the healing process with CSE treatment. CSE treatment did not show any adverse haematological and histopathological changes in the visceral organs of mice. The level of serum TNF-α was found to be significantly lower with CSE treatment. CSE was found to be rich in phenol, flavonoids, tocopherol, carotene and phytosteroids. The anti-inflammatory and immunomodulatory role of CSE against hapten-induced deleterious DTH inflammation suggests its therapeutic potential in treating inflammatory diseases and combating infections.
{"title":"Anti-inflammatory Property of Ethanolic Extract \u2028of Cleome spinosa Leaves in an In Vivo Model of Delayed-type Hypersensitivity","authors":"Torisa Roy, T. Mazumder, Priyanka Sharma, Tamali Roy, T. Nag, Samik Bindu, S. Dasgupta, H. Yasmin","doi":"10.1177/0976500x241253645","DOIUrl":"https://doi.org/10.1177/0976500x241253645","url":null,"abstract":"Delayed-type hypersensitivity (DTH) reactions represent a clinically important class of immune responses that have wide-ranging implications in various health and disease conditions. The existing anti-inflammatory drugs to treat DTH have several shortcomings including severe side-effects. Thus, a new plant-derived anti-inflammatory drug with no or less toxicity would be effective in treating DTH. The Cleome genus has been routinely used to cure various ailments including inflammation. This study investigates the anti-inflammatory properties of the ethanolic leaf extract of Cleome spinosa (CSE) in a DTH model for the first time. DTH response was induced by 2, 4-di nitro-fluorobenzene in the mouse foot pad. Histological sectioning of the paw was carried out to find changes in the architecture of the tissue. Serum tumour necrosis factor-alpha (TNF-α) was estimated through enzyme linked immunosorbent assay (ELISA), and the bioactive compounds present in CSE were analysed through reversed phase-high-performance liquid chromatography . With CSE treatment, the oedema in the resensitized paw alleviated faster with no loss of digits compared to the controls. Histological study of the resensitized paw showed less dermal and sub-dermal thickening and less collagen deposition that regained normal tissue architecture during the healing process with CSE treatment. CSE treatment did not show any adverse haematological and histopathological changes in the visceral organs of mice. The level of serum TNF-α was found to be significantly lower with CSE treatment. CSE was found to be rich in phenol, flavonoids, tocopherol, carotene and phytosteroids. The anti-inflammatory and immunomodulatory role of CSE against hapten-induced deleterious DTH inflammation suggests its therapeutic potential in treating inflammatory diseases and combating infections.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141370800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-08DOI: 10.1177/0976500x241253648
Jagdish Chand, Hannah Lalengzuali Fanai, A. S. Antony, Gomathy Subramanian
This review article explores the relationship between alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease (PD), focusing on the role of hypoxia as an intermediate factor. The interaction between alpha-synuclein and mitochondria, particularly through membranal lipids such as cardiolipins, is highlighted as a key factor in mitochondrial disruption and neurodegeneration. Hypoxia, caused by oxygen deprivation, is identified as a crucial link between alpha-synuclein and mitochondrial regulation, leading to neuronal death in PD. The article also discusses the involvement of other proteins, such as peroxisome proliferator-activated receptor gamma coactivator, Sirtuin-1, Sirtuin-3 and adenosine monophosphate-activated protein kinase, in maintaining mitochondrial biogenesis during hypoxia. The study emphasizes the need for further research to understand the complex molecular interactions causing Lewy body aggregation, improper mitochondrial functioning and neurodegeneration in PD, with a specific focus on the role of hypoxia. Alpha-synuclein aggregation disrupts mitochondrial respiration, leading to mitochondrial dysfunction and increased production of reactive oxygen species. Mitochondrial dysfunction, in turn, causes neurodegeneration in PD. Oligomeric alpha-synuclein results in mitochondrial dysfunction, lethal synaptic disruption and reduced adenosine triphosphate generation. Oligomeric alpha-synuclein also increases the accumulation of mitochondrial rho nucleotide guanosine triphosphate, leading to delayed mitophagy. Hypoxia, another factor in PD, alters both alpha-synuclein and mitochondria. Controlling hypoxia reduces the oligomerization of alpha-synuclein. The interaction between alpha-synuclein and mitochondria is complex, and determining the primary player in inducing the other is still debatable.
{"title":"Neurotoxicity by Hypoxia an Intermediate Between Alpha-synuclein and Mitochondrial Dysfunction in Parkinson’s Disease","authors":"Jagdish Chand, Hannah Lalengzuali Fanai, A. S. Antony, Gomathy Subramanian","doi":"10.1177/0976500x241253648","DOIUrl":"https://doi.org/10.1177/0976500x241253648","url":null,"abstract":"This review article explores the relationship between alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease (PD), focusing on the role of hypoxia as an intermediate factor. The interaction between alpha-synuclein and mitochondria, particularly through membranal lipids such as cardiolipins, is highlighted as a key factor in mitochondrial disruption and neurodegeneration. Hypoxia, caused by oxygen deprivation, is identified as a crucial link between alpha-synuclein and mitochondrial regulation, leading to neuronal death in PD. The article also discusses the involvement of other proteins, such as peroxisome proliferator-activated receptor gamma coactivator, Sirtuin-1, Sirtuin-3 and adenosine monophosphate-activated protein kinase, in maintaining mitochondrial biogenesis during hypoxia. The study emphasizes the need for further research to understand the complex molecular interactions causing Lewy body aggregation, improper mitochondrial functioning and neurodegeneration in PD, with a specific focus on the role of hypoxia. Alpha-synuclein aggregation disrupts mitochondrial respiration, leading to mitochondrial dysfunction and increased production of reactive oxygen species. Mitochondrial dysfunction, in turn, causes neurodegeneration in PD. Oligomeric alpha-synuclein results in mitochondrial dysfunction, lethal synaptic disruption and reduced adenosine triphosphate generation. Oligomeric alpha-synuclein also increases the accumulation of mitochondrial rho nucleotide guanosine triphosphate, leading to delayed mitophagy. Hypoxia, another factor in PD, alters both alpha-synuclein and mitochondria. Controlling hypoxia reduces the oligomerization of alpha-synuclein. The interaction between alpha-synuclein and mitochondria is complex, and determining the primary player in inducing the other is still debatable.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 47","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141370260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.1177/0976500x241245481
Shifana Ali, Ahmed Ziyad, K. S. R. Pai, Anju Muraleedharan, Adhithya Gopan, Raghavendra Upadhya, R. Seetharam, K. Manokaran
Di-(2-ethylhexyl) phthalate (DEHP), a plasticizer compound affecting female reproduction, leads to scenarios, such as polycystic ovarian syndrome (PCOS) and infertility through oxidative stress (OS) mechanisms. Ascorbic acid (AA) is one of the antioxidants in infertility issues. The present study investigates the ameliorative effect of AA on DEHP-induced ovarian toxicity in pubertal female Wistar rats. Thirty female Wistar rats of four weeks of age were stratified into five groups. Group I was treated with corn oil (Vehicle), groups II and III with low and high dose DEHP, and groups IV and V with low and high dose DEHP+AA were administered for 30 days. Increased body weight gain was noted in DEHP groups. Estradiol hormone was considerably reduced, whereas progesterone levels were increased in both low- and high-dose DEHP-treated groups. DEHP+AA groups have shown significant ( p < 0.005) protection of these hormone levels as equal to the control group. The high-dose DEHP group shows an increased, ovarian estrogen receptor (ER) alpha, ER-beta, and progesterone receptor gene expression, and DEHP+AA groups have significantly ( p < 0.005) showed expression similar to the control. OS was noted with decreased superoxide dismutase and increased malondialdehyde expression in Group III (GR III) compared to control, whereas the DEHP+AA treated group significantly protected OS by restoring the expression levels. DEHP-treated groups show elevated levels of both Bcl-2 and BAX which is specific to apoptotic expression and restored by AA treatment ( p < 0.005). Evidence suggests that AA may protect against DEHP-induced ovarian toxicity by decreasing OS levels, improving folliculogenesis, and restoring the hormonal with receptor level alterations.
{"title":"Influence of Ascorbic Acid on Di-(2-Ethylhexyl) Phthalate-induced Ovarian Gene Alterations in Pubertal Female Wistar Rats","authors":"Shifana Ali, Ahmed Ziyad, K. S. R. Pai, Anju Muraleedharan, Adhithya Gopan, Raghavendra Upadhya, R. Seetharam, K. Manokaran","doi":"10.1177/0976500x241245481","DOIUrl":"https://doi.org/10.1177/0976500x241245481","url":null,"abstract":"Di-(2-ethylhexyl) phthalate (DEHP), a plasticizer compound affecting female reproduction, leads to scenarios, such as polycystic ovarian syndrome (PCOS) and infertility through oxidative stress (OS) mechanisms. Ascorbic acid (AA) is one of the antioxidants in infertility issues. The present study investigates the ameliorative effect of AA on DEHP-induced ovarian toxicity in pubertal female Wistar rats. Thirty female Wistar rats of four weeks of age were stratified into five groups. Group I was treated with corn oil (Vehicle), groups II and III with low and high dose DEHP, and groups IV and V with low and high dose DEHP+AA were administered for 30 days. Increased body weight gain was noted in DEHP groups. Estradiol hormone was considerably reduced, whereas progesterone levels were increased in both low- and high-dose DEHP-treated groups. DEHP+AA groups have shown significant ( p < 0.005) protection of these hormone levels as equal to the control group. The high-dose DEHP group shows an increased, ovarian estrogen receptor (ER) alpha, ER-beta, and progesterone receptor gene expression, and DEHP+AA groups have significantly ( p < 0.005) showed expression similar to the control. OS was noted with decreased superoxide dismutase and increased malondialdehyde expression in Group III (GR III) compared to control, whereas the DEHP+AA treated group significantly protected OS by restoring the expression levels. DEHP-treated groups show elevated levels of both Bcl-2 and BAX which is specific to apoptotic expression and restored by AA treatment ( p < 0.005). Evidence suggests that AA may protect against DEHP-induced ovarian toxicity by decreasing OS levels, improving folliculogenesis, and restoring the hormonal with receptor level alterations.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"20 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140966834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.1177/0976500x241246402
Reuben P. Syiem, J. Wahlang, Krishnamoorthi R., Pavan B. Kalyan, Diana Nahakpam, A. J. Langstieh
Anxiety disorders, bipolar disorder, and depression are prevalent mental health issues that have a substantial impact on both individuals and the community. Many people continue to have symptoms and do not get the right kind of relief from their existing drugs, even after trying conventional therapy methods. Therefore, to enhance the current treatment modalities and patient results, new therapeutic alternatives are required. In recent years, there has been an increase in interest in N-acetylcysteine (NAC) because of its many biological benefits, including its ability to modulate glutamate levels and its antioxidant and anti-inflammatory properties. According to studies, NAC has encouraging antidepressant properties and may help treat bipolar disease by stabilizing mood and reducing the risk of relapses. Furthermore, through lowering oxidative stress and modifying neurotransmitter networks, NAC has been shown to lessen the symptoms of anxiety. The preclinical and clinical research examining the efficacy of NAC in depression, bipolar disorders, and anxiety are thoroughly analyzed in this review. Books were reviewed and medical and scientific literature found in MEDLINE and PubMed were analyzed for an assessment of NAC’s therapeutic potential in psychiatric illnesses such as anxiety, depression, and bipolar disorder. NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. Performing a thorough clinical study will facilitate proper understanding its efficacy, safety and mechanisms of action.
{"title":"Exploring the Novel Therapeutic Potential of N-acetylcysteine in Depression, Bipolar Disorders, and Anxiety","authors":"Reuben P. Syiem, J. Wahlang, Krishnamoorthi R., Pavan B. Kalyan, Diana Nahakpam, A. J. Langstieh","doi":"10.1177/0976500x241246402","DOIUrl":"https://doi.org/10.1177/0976500x241246402","url":null,"abstract":"Anxiety disorders, bipolar disorder, and depression are prevalent mental health issues that have a substantial impact on both individuals and the community. Many people continue to have symptoms and do not get the right kind of relief from their existing drugs, even after trying conventional therapy methods. Therefore, to enhance the current treatment modalities and patient results, new therapeutic alternatives are required. In recent years, there has been an increase in interest in N-acetylcysteine (NAC) because of its many biological benefits, including its ability to modulate glutamate levels and its antioxidant and anti-inflammatory properties. According to studies, NAC has encouraging antidepressant properties and may help treat bipolar disease by stabilizing mood and reducing the risk of relapses. Furthermore, through lowering oxidative stress and modifying neurotransmitter networks, NAC has been shown to lessen the symptoms of anxiety. The preclinical and clinical research examining the efficacy of NAC in depression, bipolar disorders, and anxiety are thoroughly analyzed in this review. Books were reviewed and medical and scientific literature found in MEDLINE and PubMed were analyzed for an assessment of NAC’s therapeutic potential in psychiatric illnesses such as anxiety, depression, and bipolar disorder. NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. Performing a thorough clinical study will facilitate proper understanding its efficacy, safety and mechanisms of action.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"20 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background:The term “gout” refers to a broad clinical spectrum of diseases, including common and complex forms of arthritis, that affect multiple joints in a patient due to an elevated serum urate concentration. Purpose: The study aims to compare the efficacy and safety of selective cyclooxygenase-2 (COX-2) inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of acute gout, as well as to conduct a meta-analysis on safety. Methods: As of December 2021, the literature search was conducted using authorised electronic databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Results: There were seven investigations included in this study’s findings. Three COX-2 inhibitors, etoricoxib, celecoxib, and meloxicam, were reportedly compared to indomethacin or diclofenac. Four hours after the initial dose, 120 mg of etoricoxib reduces pain and inflammation by diminishing erythema. At higher dosages, celecoxib is more effective than at lower doses. Meloxicam has the same efficacy as NSAIDs. The subgroup analysis revealed that the risk of adverse events was 8.0% lower in the COX-2 inhibitors group than in the non-selective NSAIDs group (risk ratio = 0.92, 95% confidence interval = 0.60 to 0.40, p-value = 0.5). Conclusion: Etoricoxib, a COX-2 inhibitor, has a more potent effect and may be more effective than nonselective NSAIDs. COX-2 inhibitors are more well tolerated and reduce the risk of adverse gastrointestinal events more effectively than nonselective NSAIDs. In the treatment of gout, nonselective NSAIDs may be a suitable alternative to COX-2 inhibitors.
{"title":"A Systematic Review and Meta-analysis of Selective Cyclooxygenase-2 Inhibitors and Non-selective Non-steroidal Anti-inflammatory Drugs for Acute Gout","authors":"Swathy Govindaswamy, Kavya Ponnusamy, Indhumathi *S., Vineeth Anil, Jayalakshmi Venugopal, Dhivya P. Sundaram","doi":"10.1177/0976500x241240629","DOIUrl":"https://doi.org/10.1177/0976500x241240629","url":null,"abstract":"Background:The term “gout” refers to a broad clinical spectrum of diseases, including common and complex forms of arthritis, that affect multiple joints in a patient due to an elevated serum urate concentration. Purpose: The study aims to compare the efficacy and safety of selective cyclooxygenase-2 (COX-2) inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of acute gout, as well as to conduct a meta-analysis on safety. Methods: As of December 2021, the literature search was conducted using authorised electronic databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Results: There were seven investigations included in this study’s findings. Three COX-2 inhibitors, etoricoxib, celecoxib, and meloxicam, were reportedly compared to indomethacin or diclofenac. Four hours after the initial dose, 120 mg of etoricoxib reduces pain and inflammation by diminishing erythema. At higher dosages, celecoxib is more effective than at lower doses. Meloxicam has the same efficacy as NSAIDs. The subgroup analysis revealed that the risk of adverse events was 8.0% lower in the COX-2 inhibitors group than in the non-selective NSAIDs group (risk ratio = 0.92, 95% confidence interval = 0.60 to 0.40, p-value = 0.5). Conclusion: Etoricoxib, a COX-2 inhibitor, has a more potent effect and may be more effective than nonselective NSAIDs. COX-2 inhibitors are more well tolerated and reduce the risk of adverse gastrointestinal events more effectively than nonselective NSAIDs. In the treatment of gout, nonselective NSAIDs may be a suitable alternative to COX-2 inhibitors.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"64 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140979088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Head and neck cancers (HNC) account for 5% of all malignant tumours, but 80% of patients experience pain. As per the WHO analgesic ladder, analgesics are a cornerstone for the management of pain in HNC patients. Our study aims to analyse the prescribing pattern of analgesic drugs in patients with HNC pain. A prospective, continuous, observational study was conducted among patients with HNC pain. Demographics, detailed history of pain (type, duration, location and Numerical Rating Scale [NRS] score), details of drugs prescribed and any adverse drug reactions (ADRs) were recorded at baseline visit and at first, second and sixth month follow-up. Descriptive statistics were used to analyse the above parameters. The mean reduction in NRS was analysed by the Z test. Out of 145 patients, 118 (81.37%) were male and 27 (18.62%) were female. The mean age of patients was 51.89 + 7.07 years. Tramadol (81.37%) followed by morphine (62.75%) were the commonly prescribed analgesics. Amitriptyline (20%) followed by pregabalin (19.31%) were commonly prescribed adjuvant analgesics. A statistically significant reduction in mean NRS was found at each follow-up visit ( p < .05). A total of 50 ADRs were observed. Constipation (38%) and drowsiness (24%) were the most frequently reported ADRs, with morphine and tramadol being the most common suspected causal drugs. Tramadol and morphine were frequently prescribed analgesics in patients with HNC pain in accordance with the WHO analgesic ladder. The majority of patients with HNC pain achieved a significant reduction in NRS pain scores at the end of six months.
{"title":"Evaluation of Pharmacotherapy of Cancer \u2028Pain in Patients with Head and Neck Cancer \u2028at a Tertiary Care Teaching Hospital","authors":"Shyam Vacchani, Megha Shah, Chetna Desai, Priti Sanghvi","doi":"10.1177/0976500x241246414","DOIUrl":"https://doi.org/10.1177/0976500x241246414","url":null,"abstract":"Head and neck cancers (HNC) account for 5% of all malignant tumours, but 80% of patients experience pain. As per the WHO analgesic ladder, analgesics are a cornerstone for the management of pain in HNC patients. Our study aims to analyse the prescribing pattern of analgesic drugs in patients with HNC pain. A prospective, continuous, observational study was conducted among patients with HNC pain. Demographics, detailed history of pain (type, duration, location and Numerical Rating Scale [NRS] score), details of drugs prescribed and any adverse drug reactions (ADRs) were recorded at baseline visit and at first, second and sixth month follow-up. Descriptive statistics were used to analyse the above parameters. The mean reduction in NRS was analysed by the Z test. Out of 145 patients, 118 (81.37%) were male and 27 (18.62%) were female. The mean age of patients was 51.89 + 7.07 years. Tramadol (81.37%) followed by morphine (62.75%) were the commonly prescribed analgesics. Amitriptyline (20%) followed by pregabalin (19.31%) were commonly prescribed adjuvant analgesics. A statistically significant reduction in mean NRS was found at each follow-up visit ( p < .05). A total of 50 ADRs were observed. Constipation (38%) and drowsiness (24%) were the most frequently reported ADRs, with morphine and tramadol being the most common suspected causal drugs. Tramadol and morphine were frequently prescribed analgesics in patients with HNC pain in accordance with the WHO analgesic ladder. The majority of patients with HNC pain achieved a significant reduction in NRS pain scores at the end of six months.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"35 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140980074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-08DOI: 10.1177/0976500x241246412
Venumula Vikram Reddy, Dinakar Mallem, Sonnaila Rama Krishna, V. Kotra, Wen-Han Chooi, K. Goh, L. Ming, M. Kanakal, Syed Atif Abbas, Khairulanwar Husain
Background: Studies indicated that smoking alters the response to anesthetics and alters the outcome of perioperative care. A full understanding of the impact of smoking cessation to enhance surgical outcomes is pertinent. Purpose: This research aimed to compare perioperative cardiopulmonary complications in smokers and non-smokers during elective surgery under general anesthesia. We aimed to determine the incidence of complications in patients with a history of smoking, identify those at an increased risk, and assess the relationship between smoking duration and complications Methods: A total of 100 patients, comprising 50 smokers and 50 non-smokers, were enrolled in the study. Various parameters, including heart rate increase during intubation, severe coughing, bronchospasm, oral secretions, oxygen desaturation, reintubation, opioid antagonist use, pulmonary edema, and other cardiopulmonary events, were assessed perioperatively. Statistical analysis involved both continuous and categorical variables. For continuous variables, the Student’s t-test and the Mann–Whitney U test were used for normally and non-normally distributed data, respectively. For categorical variables, chi-squared tests were employed. Sub-group analysis assessed the influence of smoking duration on the measured parameters. Results: Smokers exhibited significantly higher incidences of severe coughing, heart rate elevation during intubation, and bronchospasm compared to non-smokers. Additionally, smokers experienced more pronounced oxygen desaturation throughout the perioperative period. Furthermore, a longer history of smoking was associated with an increased risk of complications, with individuals smoking for 10 or more years displaying a higher incidence of adverse events. Conclusion: Smokers, particularly those with extended smoking histories, are at an increased risk of cardiopulmonary complications during elective surgery under general anesthesia. Emphasizing preoperative optimization, meticulous airway management, and smoking cessation support is essential to mitigate these risks. The study underscores the significance of these measures for enhancing perioperative safety and calls for further research to explore the long-term impacts and patient satisfaction associated with these interventions. These steps are essential not only for perioperative care but also for long-term health benefits among this patient population.
背景:研究表明,吸烟会改变对麻醉剂的反应,并改变围手术期护理的结果。充分了解戒烟对提高手术效果的影响非常重要。目的:本研究旨在比较吸烟者和非吸烟者在全身麻醉下进行择期手术时的围术期心肺并发症。我们旨在确定有吸烟史的患者的并发症发生率,识别风险增加的患者,并评估吸烟时间与并发症之间的关系:研究共招募了 100 名患者,包括 50 名吸烟者和 50 名非吸烟者。围手术期评估了各种参数,包括插管时心率增快、剧烈咳嗽、支气管痉挛、口腔分泌物、氧饱和度降低、重新插管、阿片类拮抗剂的使用、肺水肿和其他心肺事件。统计分析包括连续变量和分类变量。对于连续变量,正态分布和非正态分布数据分别采用学生 t 检验和 Mann-Whitney U 检验。对于分类变量,则采用卡方检验。分组分析评估了吸烟时间对测量参数的影响。结果显示与非吸烟者相比,吸烟者严重咳嗽、插管时心率升高和支气管痉挛的发生率明显更高。此外,吸烟者在整个围手术期会出现更明显的氧饱和度降低。此外,吸烟史越长,发生并发症的风险越高,吸烟 10 年或 10 年以上者发生不良事件的几率更高。结论:吸烟者,尤其是有长期吸烟史的吸烟者,在全身麻醉下进行择期手术时发生心肺并发症的风险更高。强调术前优化、细致的气道管理和戒烟支持对降低这些风险至关重要。这项研究强调了这些措施对提高围手术期安全性的重要意义,并呼吁进一步开展研究,探讨这些干预措施的长期影响和患者满意度。这些措施不仅对围手术期护理至关重要,而且对这一患者群体的长期健康益处也至关重要。
{"title":"Perioperative Cardiopulmonary Complications in Smokers and Non-smokers Undergoing Elective Surgery: A Prospective Study","authors":"Venumula Vikram Reddy, Dinakar Mallem, Sonnaila Rama Krishna, V. Kotra, Wen-Han Chooi, K. Goh, L. Ming, M. Kanakal, Syed Atif Abbas, Khairulanwar Husain","doi":"10.1177/0976500x241246412","DOIUrl":"https://doi.org/10.1177/0976500x241246412","url":null,"abstract":"Background: Studies indicated that smoking alters the response to anesthetics and alters the outcome of perioperative care. A full understanding of the impact of smoking cessation to enhance surgical outcomes is pertinent. Purpose: This research aimed to compare perioperative cardiopulmonary complications in smokers and non-smokers during elective surgery under general anesthesia. We aimed to determine the incidence of complications in patients with a history of smoking, identify those at an increased risk, and assess the relationship between smoking duration and complications Methods: A total of 100 patients, comprising 50 smokers and 50 non-smokers, were enrolled in the study. Various parameters, including heart rate increase during intubation, severe coughing, bronchospasm, oral secretions, oxygen desaturation, reintubation, opioid antagonist use, pulmonary edema, and other cardiopulmonary events, were assessed perioperatively. Statistical analysis involved both continuous and categorical variables. For continuous variables, the Student’s t-test and the Mann–Whitney U test were used for normally and non-normally distributed data, respectively. For categorical variables, chi-squared tests were employed. Sub-group analysis assessed the influence of smoking duration on the measured parameters. Results: Smokers exhibited significantly higher incidences of severe coughing, heart rate elevation during intubation, and bronchospasm compared to non-smokers. Additionally, smokers experienced more pronounced oxygen desaturation throughout the perioperative period. Furthermore, a longer history of smoking was associated with an increased risk of complications, with individuals smoking for 10 or more years displaying a higher incidence of adverse events. Conclusion: Smokers, particularly those with extended smoking histories, are at an increased risk of cardiopulmonary complications during elective surgery under general anesthesia. Emphasizing preoperative optimization, meticulous airway management, and smoking cessation support is essential to mitigate these risks. The study underscores the significance of these measures for enhancing perioperative safety and calls for further research to explore the long-term impacts and patient satisfaction associated with these interventions. These steps are essential not only for perioperative care but also for long-term health benefits among this patient population.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140999254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-08DOI: 10.1177/0976500x241240643
Aditya Bubna, Vinayak Viplav
Background: Ustekinumab is an interleukin 12/23 inhibitor, approved by the US-FDA for the management of moderate-to-severe plaque psoriasis and psoriatic arthropathy. Purpose: This review aims to describe the dermatological implications and applications of ustekinumab. Methods: PubMed and Google Scholar were searched for scholarly articles related to ustekinumab and its utility in dermatology using the search terms “Ustekinumab” AND “Psoriasis” AND “dermatological diseases”. Studies utilising Ustekinumab in psoriasis and other dermatological indications were analysed and formulated into a systematic review discussing the utility of the drug in psoriasis, as well as other dermatological conditions. Results: Ustekinumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy, as well as other dermatological disorders like hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, Behcet’s disease, lupus erythematosus, alopecia areata and pyoderma gangrenosum. Conclusion: Ustekinumab’s usage is not limited to psoriasis. Its benefit extends to many more dermatological conditions. It is considered to be the biologic of choice in childhood psoriasis and adult psoriatic patients with concurrent Crohn’s disease. Besides, it has an acceptable safety profile.
背景介绍乌斯特库单抗是一种白细胞介素 12/23 抑制剂,已获美国 FDA 批准用于治疗中重度斑块状银屑病和银屑病关节病。目的:本综述旨在描述乌斯特库单抗在皮肤病学方面的意义和应用。研究方法使用 "Ustekinumab"、"银屑病 "和 "皮肤病 "等关键词在 PubMed 和 Google Scholar 上搜索与乌司替尼及其在皮肤病学中的应用相关的学术文章。对使用 Ustekinumab 治疗银屑病和其他皮肤病适应症的研究进行了分析,并撰写了一篇系统综述,讨论该药物在银屑病和其他皮肤病中的应用。研究结果乌司他单抗是治疗银屑病和银屑病关节病以及其他皮肤病(如化脓性扁平苔藓、扁平苔藓、红斑狼疮、白塞氏病、红斑狼疮、斑秃和脓疱疮)的重要生物制剂。结论Ustekinumab 的用途不仅限于银屑病。它还能治疗更多的皮肤病。它被认为是治疗儿童银屑病和并发克罗恩病的成年银屑病患者的首选生物制剂。此外,它的安全性也是可以接受的。
{"title":"Ustekinumab: In Psoriasis and Beyond —A Derm atological Perspective","authors":"Aditya Bubna, Vinayak Viplav","doi":"10.1177/0976500x241240643","DOIUrl":"https://doi.org/10.1177/0976500x241240643","url":null,"abstract":"Background: Ustekinumab is an interleukin 12/23 inhibitor, approved by the US-FDA for the management of moderate-to-severe plaque psoriasis and psoriatic arthropathy. Purpose: This review aims to describe the dermatological implications and applications of ustekinumab. Methods: PubMed and Google Scholar were searched for scholarly articles related to ustekinumab and its utility in dermatology using the search terms “Ustekinumab” AND “Psoriasis” AND “dermatological diseases”. Studies utilising Ustekinumab in psoriasis and other dermatological indications were analysed and formulated into a systematic review discussing the utility of the drug in psoriasis, as well as other dermatological conditions. Results: Ustekinumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy, as well as other dermatological disorders like hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, Behcet’s disease, lupus erythematosus, alopecia areata and pyoderma gangrenosum. Conclusion: Ustekinumab’s usage is not limited to psoriasis. Its benefit extends to many more dermatological conditions. It is considered to be the biologic of choice in childhood psoriasis and adult psoriatic patients with concurrent Crohn’s disease. Besides, it has an acceptable safety profile.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140999231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: In recent years, ellagic acid has emerged as a focal point in pharmacological research, showcasing promising developments and potential therapeutic applications as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 for the treatment of cancer, as a shielding impact that stimulates sirtuin 6 (SIRT 6), against nephrotoxicity induced by cisplatin, as adjuvant treatment in sickle cell anemia, as antiaging and to avoid mild cognitive impairment. Purpose: This review provides a concise overview of the latest advancements in ellagic acid research, highlighting novel pharmacological findings and emerging trends. Methods: A comprehensive search of relevant literature was conducted to gather information on the pharmacological properties and therapeutic applications of ellagic acid. Studies investigating its antioxidant properties, anti-inflammatory effects, molecular interactions, and therapeutic implications were included in the analysis. Results: The review summarizes the multifaceted pharmacological landscape of ellagic acid, encompassing its antioxidant properties, anti-inflammatory effects, and potential therapeutic applications. It sheds light on its evolving role in modern medicine and underscores its significance as a promising avenue for future pharmaceutical exploration. Conclusion: The recent strides in ellagic acid development highlight its potential as a valuable therapeutic agent in various health conditions. Further research into its molecular interactions and clinical applications is warranted to fully harness its therapeutic potential and improve patient outcomes.
{"title":"A Review on Pharmacological Advancement of Ellagic Acid","authors":"Pougang Golmei, Sweta Kasna, Kumar Probin Roy, Sachin Kumar","doi":"10.1177/0976500x241240634","DOIUrl":"https://doi.org/10.1177/0976500x241240634","url":null,"abstract":"Background: In recent years, ellagic acid has emerged as a focal point in pharmacological research, showcasing promising developments and potential therapeutic applications as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 for the treatment of cancer, as a shielding impact that stimulates sirtuin 6 (SIRT 6), against nephrotoxicity induced by cisplatin, as adjuvant treatment in sickle cell anemia, as antiaging and to avoid mild cognitive impairment. Purpose: This review provides a concise overview of the latest advancements in ellagic acid research, highlighting novel pharmacological findings and emerging trends. Methods: A comprehensive search of relevant literature was conducted to gather information on the pharmacological properties and therapeutic applications of ellagic acid. Studies investigating its antioxidant properties, anti-inflammatory effects, molecular interactions, and therapeutic implications were included in the analysis. Results: The review summarizes the multifaceted pharmacological landscape of ellagic acid, encompassing its antioxidant properties, anti-inflammatory effects, and potential therapeutic applications. It sheds light on its evolving role in modern medicine and underscores its significance as a promising avenue for future pharmaceutical exploration. Conclusion: The recent strides in ellagic acid development highlight its potential as a valuable therapeutic agent in various health conditions. Further research into its molecular interactions and clinical applications is warranted to fully harness its therapeutic potential and improve patient outcomes.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141014671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}